B-CELL NON-HODGKIN LYMPHOMA

This early-phase trial is testing whether giving special immune cells (CMV-specific CD19-CAR T cells) along with a vaccine (CMV-MVA triplex) after a stem cell transplant can safely help prevent B-cell non-Hodgkin lymphoma from returning. About 15 people with intermediate or high-…

This phase 2 trial tests whether adding the drug epcoritamab to standard chemotherapy (EPOCH-R) is safe and effective for people with aggressive B-cell non-Hodgkin lymphoma. Epcoritamab is a bispecific antibody that helps the immune system attack cancer cells. The study will enro…

This study tests a new treatment called CTX112 for people with B-cell cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. CTX112 uses CRISPR gene editing to modify immune cells from a healthy donor, making them target and kill cancer …

This early-stage trial is testing a drug called loncastuximab tesirine (ZYNLONTA) combined with other anti-cancer agents in people with relapsed or refractory B-cell non-Hodgkin lymphoma, a blood cancer that has come back or not responded to prior treatments. The main goal is to …

The TAPUR study is testing whether giving targeted cancer drugs based on a tumor's specific genetic changes can help people with advanced solid tumors, lymphoma, or multiple myeloma. About 4200 participants whose cancer has stopped responding to standard treatments will receive o…

This early-phase trial is testing a new type of cell therapy made from cord blood. The cells are engineered to recognize and attack a protein called CD19 on lymphoma cells, plus they carry extra signals (IL-10 and IL-15) to help them work better. The study will enroll 24 adults w…

This early-phase trial is testing a new version of CAR T-cell therapy that has been modified to improve its energy use, potentially making the cells more effective. It is for adults with certain types of B-cell lymphoma or chronic lymphocytic leukemia that have come back or not r…

This early-phase study tests a new immune cell therapy called CT1190B CAR-T in 27 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatments. The main goals are to check safety and find the right dose, while also looking at how well it shrinks…

This early-phase trial is testing a new type of CAR T-cell therapy called MC10029 for people with B-cell blood cancers that have returned or not responded to treatment. The therapy involves taking a patient's own immune cells, modifying them in the lab to target a protein called …

This early-stage study tests an experimental drug called SAR448501 in about 96 adults with B-cell non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. The main goal is to find the safest and most effective dose by monitoring side effects …

This study tests whether giving cancer drugs that target specific genetic changes in a person's tumor can help shrink or control their cancer. It includes 720 adults with advanced solid tumors, lymphoma, or multiple myeloma who have no standard treatment options. Participants rec…

This study tests a new drug called AZD4512, alone or with other cancer medicines, in adults with relapsed or refractory B-cell Non-Hodgkin lymphoma (a type of blood cancer). The goal is to find safe doses and check if the drug shrinks tumors. About 91 participants will take part …

This early-stage study is testing an experimental drug called CC312 in people with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The main goals are to check the drug's safety and find the right dose. About 44 a…

This study tests a new treatment for people with advanced B-cell lymphoma or leukemia that has returned or not improved after standard therapy. Researchers take a patient's own T-cells, add a special receptor (CAR) that targets the CD19 protein on cancer cells, and also add extra…

This study is for children and young people with B-cell Non-Hodgkin lymphoma that has come back or not responded to treatment. Current treatments are harsh and only work for about 30 out of 100 children. The trial will test several new medicines, alone or with chemotherapy, to se…

This study tests a new drug called surovatamig (AZD0486) in adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior treatments. The goal is to see if the drug can shrink or eliminate tumors. About 240 participants will receive the dr…

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. The drug works like a guided missile, targeting a protein (CD19) on cancer cells to deliver a toxic payload. The study aims to find…

This early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…

This study tests a new type of CAR-T cell therapy made locally for children whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to treatment. The therapy uses the patient's own immune cells, modified to target and kill cancer ce…

This study tests whether giving a special immune cell treatment (CD19 CAR-T) right after a stem cell transplant can help people with a hard-to-treat type of B-cell lymphoma. The trial involves 16 adults whose cancer has come back or not responded to standard treatments. The main …

This study tests a new drug called AZD0486, alone or with other cancer drugs, in people with B-cell blood cancers like certain lymphomas and leukemias. The goal is to see if it is safe and helps shrink or control the cancer. About 408 adults will take part in this early-phase tri…

This early-stage trial tests a new treatment called DuoCAR20.19.22-D95 for adults with B-cell lymphoma or leukemia that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in the lab to better recognize and attack…

This study tests whether a geriatric assessment—checking physical function, thinking skills, and nutrition—followed by tailored support (physical therapy, delirium prevention, and nutritional help) can help people aged 60 and older recover faster after CAR-T therapy for B-cell no…

This study follows about 40 people who received Miltenyi CAR T cell therapy at least one year ago. Researchers will track side effects, overall health, and any return of cancer. The goal is to understand the long-term safety of this treatment.